Genmab Reports 36% Revenue Growth in H1 2024
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
- Latest
- Trending
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
"Denmark stocks dipped with OMX Copenhagen 20 down 0.87%. Tryg A/S up 4.05%, while Vestas Wind Systems dropped 3.76%. Crude ...
Denmark stocks fell as various sectors weighed on shares, with falling stocks outnumbering advancing ones. Genmab reached a three-year low. ...
S&P 500 and European stocks decline, while Asian stocks rally. Commodities show gains, and the Wall Street Journal Dollar Index ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.